Drug Resistance Associated with Antiangiogenesis Therapy

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2009 Jun 16

PMID 19524042

Citations 19

Authors

Hans Petter Eikesdal

Raghu Kalluri

Affiliations

Soon will be listed here.

Abstract

Neovascularization is one of the hallmarks associated with tumor growth. In the recent years, a number of angiogenesis inhibitors have been approved for clinical use in cancer patients. However, the efficacy of antiangiogenic therapy is in most cases short-lasting, with likely drug resistance developing within a few months. It is becoming clear also that there are a subset of malignant tumors that are inherently resistant to angiogenesis inhibition. The knowledge regarding resistance mechanisms towards angiogenesis inhibitors is still evolving and here we propose some theories and in some cases provide experimental evidence.

Citing Articles

Monitoring Dual VEGF Inhibition in Human Pancreatic Tumor Xenografts With Dynamic Contrast-Enhanced Ultrasound.

Lamuraglia M, Barrois G, Le Guillou-Buffello D, Santin M, Kerbol A, Comperat E Technol Cancer Res Treat. 2020; 19:1533033819886896.

PMID: 32065066 PMC: 7026814. DOI: 10.1177/1533033819886896.

Stromal cells in breast cancer as a potential therapeutic target.

Dykes S, Hughes V, Wiggins J, Fasanya H, Tanaka M, Siemann D Oncotarget. 2018; 9(34):23761-23779.

PMID: 29805773 PMC: 5955086. DOI: 10.18632/oncotarget.25245.

Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches.

Awad D, Pulliam T, Lin C, Wilkenfeld S, Frigo D Curr Opin Pharmacol. 2018; 41:1-11.

PMID: 29609138 PMC: 6108937. DOI: 10.1016/j.coph.2018.03.002.

Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Farzam P, Johansson J, Mireles M, Jimenez-Valerio G, Martinez-Lozano M, Choe R Biomed Opt Express. 2017; 8(5):2563-2582.

PMID: 28663891 PMC: 5480498. DOI: 10.1364/BOE.8.002563.

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.

Simone V, Brunetti O, Lupo L, Testini M, Maiorano E, Simone M Int J Mol Sci. 2017; 18(2).

PMID: 28212293 PMC: 5343952. DOI: 10.3390/ijms18020418.

References

Thorpe P . Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004; 10(2):415-27. DOI: 10.1158/1078-0432.ccr-0642-03. View

Eikesdal H, Bjerkvig R, Mella O, Dahl O . Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors. Radiother Oncol. 2001; 60(2):147-54. DOI: 10.1016/s0167-8140(00)00318-2. View

Eikesdal H, Bjorkhaug S, Dahl O . Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia. 2002; 18(2):141-52. DOI: 10.1080/02656730110090712. View

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

Benelli R, Morini M, Brigati C, Noonan D, Albini A . Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. Int J Oncol. 2002; 22(1):87-91. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

Pozzi A, Moberg P, Miles L, Wagner S, Soloway P, Gardner H . Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000; 97(5):2202-7. PMC: 15778. DOI: 10.1073/pnas.040378497. View

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P . Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004; 165(1):35-52. PMC: 1618540. DOI: 10.1016/S0002-9440(10)63273-7. View

10.

Konerding M, Steinberg F, Budach V . The vascular system of xenotransplanted tumors--scanning electron and light microscopic studies. Scanning Microsc. 1989; 3(1):327-35; discussion 335-6. View

11.

Zeisberg E, Potenta S, Xie L, Zeisberg M, Kalluri R . Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67(21):10123-8. DOI: 10.1158/0008-5472.CAN-07-3127. View

12.

Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A . In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys. 2001; 49(2):443-50. DOI: 10.1016/s0360-3016(00)01470-x. View

13.

St Croix B, Rago C, Velculescu V, Traverso G, Romans K, Montgomery E . Genes expressed in human tumor endothelium. Science. 2000; 289(5482):1197-202. DOI: 10.1126/science.289.5482.1197. View

14.

Ebos J, Lee C, Christensen J, Mutsaers A, Kerbel R . Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104(43):17069-74. PMC: 2040401. DOI: 10.1073/pnas.0708148104. View

15.

Alfranca A, Lopez-Oliva J, Genis L, Lopez-Maderuelo D, Mirones I, Salvado D . PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood. 2008; 112(4):1120-8. DOI: 10.1182/blood-2007-09-112268. View

16.

Sakariassen P, Prestegarden L, Wang J, Skaftnesmo K, Mahesparan R, Molthoff C . Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci U S A. 2006; 103(44):16466-71. PMC: 1618812. DOI: 10.1073/pnas.0607668103. View

17.

Brown P . Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999; 107(1):174-80. DOI: 10.1111/j.1699-0463.1999.tb01541.x. View

18.

Gunsilius E, Duba H, Petzer A, Kahler C, Grunewald K, Stockhammer G . Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 2000; 355(9216):1688-91. DOI: 10.1016/S0140-6736(00)02241-8. View

19.

Kim E, Moore J, Huang J, Soffer S, Manley C, OToole K . All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg. 2001; 36(2):287-90. DOI: 10.1053/jpsu.2001.20691. View

20.

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R . Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318(5848):287-90. DOI: 10.1126/science.1142946. View